Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Helen Finnigan"'
Autor:
Catharina G. Faber, Nadine Attal, Giuseppe Lauria, Robert H. Dworkin, Roy Freeman, Katherine T. Dawson, Helen Finnigan, Amirhossein Hajihosseini, Himanshu Naik, Michael Serenko, Christopher J. Morris, Mona Kotecha
Publikováno v:
EClinicalMedicine, Vol 59, Iss , Pp 101971- (2023)
Summary: Background: No pharmacological treatments are specifically indicated for painful small fibre neuropathy (SFN). CONVEY, a phase 2 enriched-enrolment study, evaluated the efficacy and safety of vixotrigine, a voltage- and use-dependent sodium
Externí odkaz:
https://doaj.org/article/98dd54c83e884b6a959fad1b27b55fcf
Publikováno v:
Clinical Drug Investigation. 42:829-837
Vixotrigine is a voltage-dependent and use-dependent sodium channel blocker in development for the treatment of neuropathic pain. Metabolism of vixotrigine is primarily through glucuronidation, resulting in the major M13 metabolite. Two additional ma
Autor:
Helen Finnigan, P. Moroni-Zentgraf, A. L. Boner, Stanley J. Szefler, Christian Vogelberg, G El Azzi, Eckard Hamelmann, Mark Vandewalker, Michael Engel
Publikováno v:
Pneumologie. 71:S1-S125
Autor:
Guus M. Asijee, Leonardo M. Fabbri, Helen Finnigan, E.F.M. Wouters, Pma Calverley, Kay Tetzlaff, Claus Vogelmeier, H Watz, Bernd Disse, H. Magnussen
Publikováno v:
Pneumologie. 71:S1-S125
Autor:
Leonardo M. Fabbri, Claus Vogelmeier, Helen Finnigan, William Mezzanotte, Helgo Magnussen, Guus M. Asijee, Henrik Watz, Kay Tetzlaff, Emiel F.M. Wouters, Bernd Disse, Christoph Hallmann, Peter M.A. Calverley
Publikováno v:
American Journal of Respiratory and Critical Care Medicine, 196(9), 1219-1221. American Thoracic Society
Autor:
Kay Tetzlaff, Roberto Rodriguez-Roisin, Emiel F.M. Wouters, Helgo Magnussen, Peter M.A. Calverley, Henrik Watz, Bernd Disse, Helen Finnigan
Publikováno v:
International Journal of Chronic Obstructive Pulmonary Disease
International journal of chronic obstructive pulmonary disease, 11, 1973-1981. Dove Medical Press Ltd
International journal of chronic obstructive pulmonary disease, 11, 1973-1981. Dove Medical Press Ltd
Roberto Rodriguez-Roisin,1 Kay Tetzlaff,2,3 Henrik Watz,4 Emiel FM Wouters,5 Bernd Disse,2 Helen Finnigan,6 Helgo Magnussen,4 Peter MA Calverley7 1Respiratory Institute, Servei de Pneumologia, Hospital Clínic IDIBAPS-CIBERES, Universitat de Barcelon
Autor:
Anne Kirsten, Roberto Rodriguez-Roisin, Peter M.A. Calverley, Helen Finnigan, Eric D. Bateman, Emiel F.M. Wouters, Bernd Disse, Kay Tetzlaff, Helgo Magnussen, Henrik Watz
Publikováno v:
European Respiratory Journal, 47(2), 651-654. European Respiratory Society
Decreased FEV 1 after complete ICS withdrawal in severe COPD was not progressive and did not predict clinical changes http://ow.ly/TtYDV
Autor:
Lesley Towse, Anne Kirsten, Helen Finnigan, Marc Decramer, Peter M.A. Calverley, Ronald Dahl, Bernd Disse, Henrik Watz, Helgo Magnussen, Kay Tetzlaff
Publikováno v:
Magnussen, H, Watz, H, Kirsten, A, Decramer, M, Dahl, R, Calverley, P M A, Towse, L, Finnigan, H, Tetzlaff, K & Disse, B 2014, ' Stepwise withdrawal of inhaled corticosteroids in COPD patients receiving dual bronchodilation : WISDOM study design and rationale ', Kokyuukika, vol. 108, no. 4, pp. 593-599 . https://doi.org/10.1016/j.rmed.2014.01.002
Long-acting bronchodilators in combination with inhaled corticosteroids (ICS) are recommended to decrease the risk of recurrent exacerbations in patients with Global initiative for chronic Obstructive Lung Disease (GOLD) stage 3-4 chronic obstructive
Autor:
Eckard Hamelmann, Helen Finnigan, Petra Moroni-Zentgraf, Christian Vogelberg, Olaf Schmidt, Michael Engel, István Laki, Georges El Azzi, Mark Vandewalker
Publikováno v:
7.2 Paediatric Asthma and Allergy.
Background: Tiotropium Respimat® (tioR) has been shown to improve lung function in a Phase II study in children with moderate symptomatic asthma. Aim: To assess the efficacy of once-daily tioR add-on therapy in a Phase III trial in patients (pts) ag
Autor:
Georges El Azzi, Christian Vogelberg, Stanley J. Szefler, Michael Engel, Helen Finnigan, Eckard Hamelmann, Petra Moroni-Zentgraf, Jonathan A. Bernstein, Thomas Harper
Publikováno v:
7.2 Paediatric Asthma and Allergy.
Background: PEF is a sensitive measure of bronchoconstriction and asthma control. Phase II studies in adolescents and children with symptomatic asthma showed improvements in PEF with once-daily (QD) tiotropium Respimat ® (tioR). Aim: To assess chang